Bayer AGXSWX:BAYN 54 PS Ratio is 0.99 as of Jun. 27, 2026, which is 18% below its 10-year median of 1.20. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Bayer AG ranks better than 78.59% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bayer AG's share price is CHF42.49.
Bayer AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF42.72. Hence, Bayer AG's PS Ratio for today is 0.99.
Warning Sign:
Bayer AG stock PS Ratio (=1.02) is close to 3-year high of 1.06.
The historical rank and industry rank for Bayer AG's PS Ratio or its related term are showing as below:
XSWX:BAYN'
s PS Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.2 Max: 2.88
Current: 1.02
During the past 13 years, Bayer AG's highest PS Ratio was 2.88. The lowest was 0.40. And the median was 1.20.
XSWX:BAYN's PS Ratio is ranked better than 78.59% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs XSWX:BAYN: 1.02
Bayer AG's Revenue per Sharefor the
three
months ended in Mar. 2026 was CHF12.42.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF42.72.
Warning Sign:
Bayer AG revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Bayer AG was -2.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.70% per year.
During the past 13 years, Bayer AG's highest 3-Year average Revenue per Share Growth Rate was 11.10% per year. The lowest was -11.20% per year. And the median was 2.10% per year.
Back to Basics: PS Ratio
Bayer AG (XSWX:BAYN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Bayer AG PS Ratio Related Terms
Bayer AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Bayer AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bayer AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bayer AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bayer AG's Share Price of today is CHF42.49. Bayer AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF42.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bayer AG (XSWX:BAYN) has a PS Ratio of 0.99 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bayer AG and its competitors. This is 18% below median its historical median of 1.20. Over the past decade, Bayer AG's PS Ratio has ranged from 0.40 to 2.88. According to the industry distribution chart, Bayer AG ranks #204 out of 953 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Bayer AG's PS Ratio too high?
Bayer AG's current PS Ratio of 0.99 is 18% below median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 2.88. The Drug Manufacturers industry median PS Ratio is 2.20. Bayer AG's value of 0.99 is 55% below this industry median. Based on the distribution chart, Bayer AG ranks #204 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #204 out of 953 companies for PS Ratio. This places Bayer AG in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.20. Bayer AG's value of 0.99 is 55% below this benchmark. Historically, Bayer AG's own PS Ratio has ranged from 0.40 to 2.88 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 2.20, Bayer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current PS Ratio of 0.99 is 55% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current PS Ratio is 0.99, which is 18% below median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current PS Ratio is 0.99, which is 18% below median its 10-year median of 1.20 and 55% below the Drug Manufacturers industry median of 2.20. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current PS Ratio is 0.99 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
PS Ratio: 0.99 (18% below median its 10-year median of 1.20)
GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
Industry Position: 55% below the Drug Manufacturers median (#204 of 953)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score
Get the complete analysis for XSWX:BAYN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
